Last reviewed · How we verify
NCT04232800: RGRAW
Riboflavin for Glutamate Reduction in Alcohol Withdrawal
Phase 2 trial testing Riboflavin in Alcohol Withdrawal in 40 participants. Status unknown.
25 August 2022
Quick facts
| Lead sponsor | Oregon Health and Science University |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | basic science |
| Enrollment | 40 |
| Start date | 1 December 2021 |
| Primary completion | 25 August 2022 |
| Estimated completion | 25 October 2022 |
Drugs / interventions tested
- Riboflavin (RIBOFLAVIN) — full drug profile →
- Placebo
Conditions studied
- Alcohol Withdrawal — all drugs for Alcohol Withdrawal →
- Nutrition Disorders — all drugs for Nutrition Disorders →
- Alcohol Use Disorder — all drugs for Alcohol Use Disorder →
Sponsor
Oregon Health and Science University
Who can join
Adults 18 to 65, any sex, with Alcohol Withdrawal or Nutrition Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This RCT intends to investigate the use of oral Riboflavin (Vitamin B2) for reduction of blood glutamate levels in the setting of acute alcohol withdrawal. Participants will be patients admitted to an inpatient hospital unit diagnosed with acute alcohol withdrawal. In addition to receiving care as usual, they will be randomized to receive either 100mg TID riboflavin or an identically dosed placebo. The primary outcome measure will be blood glutamate levels. Secondary outcomes will include measures of alcohol withdrawal and alcohol craving. The investigators hypothesize that those in the riboflavin group will have lower blood levels of glutamate, as well as decreased symptoms of alcohol withdrawal.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Riboflavin supplements for blood pressure lowering in adults.
Bradbury KE, Coffey S, Earle N, Ni Mhurchu C, et al · · 2025 · PMID 41123035 · DOI 10.1002/14651858.cd015464.pub2
Verify or expand the search:
- PubMed search for NCT04232800
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Riboflavin
Trials testing the same drug.
- NCT05907850 — Effects of Riboflavin in Mitigating Muscle Soreness in Ultra-marathon Athletes · EARLY_PHASE1 · completed
- NCT05803811 — Effect of Colon Delivered Vitamin B2 on Gut Microbiota and Related Health Biomarkers in Healthy Older Adults · NA · completed
- NCT03432572 — Investigating Oral Agents for Urine Staining to Facilitate Intraoperative Observation of Ureteral Jets · EARLY_PHASE1 · completed
- NCT03151096 — Pilot Evaluation of the Effect of Riboflavin Supplementation on Blood Pressure and Possible Effect Modification by the M · NA · terminated
- NCT02863809 — Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit · Phase 1, PHASE2 · completed
Other recruiting trials for Alcohol Withdrawal
Currently open trials in the same condition.
- NCT06771037 — Use of tAN® in Alcohol Withdrawal Management · NA · recruiting
- NCT06618755 — Motivational Interviews Post Hospitalisation on Maintaining AbstiNence for 1 Year après le Sevrage en Alcool · NA · recruiting
- NCT06878287 — Bright Light Therapy During Residential Alcohol Withdrawal · NA · recruiting
- NCT04793685 — Prazosin for Alcohol Use Disorder With Withdrawal Symptoms · Phase 2 · recruiting
Other Oregon Health and Science University trials
Trials by the same sponsor.
- NCT07431970 — Assessing Construction Execution Under Sleep Impairment · NA · not yet recruiting
- NCT07309757 — Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD) · not yet recruiting
- NCT07282639 — App-Based Certified Diabetes Education Therapy (AB-CDE) · NA · not yet recruiting
- NCT07322588 — Reentry Incentives and Support for Engagement With Contingency Management · NA · not yet recruiting
- NCT07220590 — Implementing Powered Mobility in Early Childhood Settings for Children With Cerebral Palsy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04232800 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oregon Health and Science University
- Last refreshed: 29 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04232800.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing